Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 1995

Primary Completion Date

August 31, 2002

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

recombinant interferon alfa

DRUG

cisplatin

DRUG

dacarbazine

Trial Locations (24)

1000

Institut Jules Bordet, Brussels (Bruxelles)

1070

Hopital Universitaire Erasme, Brussels

4200

Instituto Portugues de Oncologia do Porto, Porto

20141

Istituto Europeo Di Oncologia, Milan

25030

CHR de Besancon - Hopital Saint-Jacques, Besançon

69373

Centre Leon Berard, Lyon

75651

CHU Pitie-Salpetriere, Paris

A-5020

Landeskrankenanstalten - Salzburg, Salzburg

B-2650

Universitair Ziekenhuis Antwerpen, Edegem

B-3000

U.Z. Gasthuisberg, Leuven

D-10117

Universitaetsklinikum Charite, Berlin

D-12200

Universitaetsklinikum Benjamin Franklin, Berlin

D-13122

Robert Roessle Klinik, Berlin

D-22765

Haematologisch-Onkologische Praxis Altona, Hamburg

D-55101

Johannes Gutenberg University, Mainz

D-68135

III Medizinische Klinik Mannheim, Mannheim

NL-6500 HB

University Medical Center Nijmegen, Nijmegen

3075 EA

Rotterdam Cancer Institute, Rotterdam

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

CH-8091

Universitaetsspital, Zurich

LS9 7TF

St. James's Hospital, Leeds

SW3 6JJ

Royal Marsden NHS Trust, London

Unknown

Southend NHS Trust Hospital, Westcliff-on-Sea

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK